JP7854780B2 - 核内受容体に対して活性の化合物 - Google Patents

核内受容体に対して活性の化合物

Info

Publication number
JP7854780B2
JP7854780B2 JP2020209927A JP2020209927A JP7854780B2 JP 7854780 B2 JP7854780 B2 JP 7854780B2 JP 2020209927 A JP2020209927 A JP 2020209927A JP 2020209927 A JP2020209927 A JP 2020209927A JP 7854780 B2 JP7854780 B2 JP 7854780B2
Authority
JP
Japan
Prior art keywords
fluoro
methyl
amino
trifluoromethyl
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020209927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021098692A (ja
JP2021098692A5 (enExample
Inventor
シュレーダー グラド サネ
サルバリー イアン
ホー ゴリアエフ アレクス
フランク トマス
イェンスビュー ニルスン セーレン
ピエロ スタシ ルイージ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuevolution AS
Original Assignee
Nuevolution AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuevolution AS filed Critical Nuevolution AS
Publication of JP2021098692A publication Critical patent/JP2021098692A/ja
Publication of JP2021098692A5 publication Critical patent/JP2021098692A5/ja
Application granted granted Critical
Publication of JP7854780B2 publication Critical patent/JP7854780B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020209927A 2019-12-20 2020-12-18 核内受容体に対して活性の化合物 Active JP7854780B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951239P 2019-12-20 2019-12-20
US62/951,239 2019-12-20

Publications (3)

Publication Number Publication Date
JP2021098692A JP2021098692A (ja) 2021-07-01
JP2021098692A5 JP2021098692A5 (enExample) 2023-12-18
JP7854780B2 true JP7854780B2 (ja) 2026-05-07

Family

ID=74003833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020209927A Active JP7854780B2 (ja) 2019-12-20 2020-12-18 核内受容体に対して活性の化合物

Country Status (6)

Country Link
US (1) US11447479B2 (enExample)
EP (1) EP4076657A1 (enExample)
JP (1) JP7854780B2 (enExample)
AU (1) AU2020405446A1 (enExample)
MX (1) MX2022007265A (enExample)
WO (1) WO2021124277A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022012205A2 (pt) 2019-12-20 2022-09-13 Nuevolution As Compostos ativos para receptores nucleares
CA3174252A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
JP7713954B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
CN113461687B (zh) * 2021-08-10 2022-04-19 四川大学华西医院 2,8-氮杂-[4,5]十螺环酮衍生物及其制备方法和用途
CN119060034B (zh) * 2024-09-02 2026-03-24 上海信诺维生物医药有限公司 一种含吡喃取代的吗啉类化合物的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514676A (ja) 2006-12-21 2010-05-06 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
WO2012020762A1 (ja) 2010-08-10 2012-02-16 アステラス製薬株式会社 へテロ環化合物
JP2017523193A (ja) 2014-08-04 2017-08-17 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ 核内受容体に対して活性な化合物

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298602A (en) 1978-10-13 1981-11-03 The Dow Chemical Company Heterocyclic substituted triazolyl phosphorous compounds and their use as insecticides
DE3737748A1 (de) 1987-11-03 1989-05-18 Schering Ag 3-arylsulfonylamino-1h-1,2,4-triazole, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider und wachstumsregulierender wirkung
DE3905714A1 (de) 1989-02-24 1990-09-06 Bayer Ag Sulfonylimino-azinylheteroazole, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung als herbizide
DE3928605A1 (de) 1989-08-30 1991-03-07 Bayer Ag Substituierte sulfonylaminoazole
GB8929022D0 (en) 1989-12-22 1990-02-28 Ici Plc Diazine derivatives
JPH04348326A (ja) 1990-07-09 1992-12-03 Sumitomo Electric Ind Ltd 有機非線形光学材料
DE4124942A1 (de) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JP3264492B2 (ja) 1992-01-13 2002-03-11 スミスクライン・ビーチャム・コーポレイション ピリジル置換イミダゾール
AU4288293A (en) 1992-04-27 1993-11-29 E.I. Du Pont De Nemours And Company Fungicidal 1,3,4-oxadiazines and 1,3,4-thiadiazines
JPH06220059A (ja) 1993-01-28 1994-08-09 Tanabe Seiyaku Co Ltd 縮合ピリミジン誘導体及びその製法
DE4427529A1 (de) 1994-08-04 1996-02-08 Bayer Ag Verfahren zur Herstellung von 1,2,4-Triazin-3,5-dionen
CA2223081C (en) 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
DE19536891A1 (de) 1995-10-04 1997-04-10 Basf Ag Neue Aminosäurederivate, ihre Herstellung und Verwendung
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
IL129825A0 (en) 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
JPH10251255A (ja) 1997-03-14 1998-09-22 Nissan Chem Ind Ltd アジン誘導体
JP2000086663A (ja) 1998-09-09 2000-03-28 Taisho Pharmaceut Co Ltd アリールテトラヒドロピリジン誘導体
EP1396489A1 (en) 1999-01-27 2004-03-10 Pfizer Products Inc. Heteroaromatic bicyclic derivatives useful as anticancer agents
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
JP2003104971A (ja) 1999-08-12 2003-04-09 Wakunaga Pharmaceut Co Ltd 新規アニリド誘導体又はその塩及びこれを含有する医薬
ATE311385T1 (de) 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
CA2396693A1 (en) 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
ES2290115T3 (es) 2000-02-01 2008-02-16 ABBOTT GMBH & CO. KG Compuestos heterociclicos y su aplicacion como inhibidores de parp.
AU2001294557A1 (en) 2000-09-11 2002-03-26 Merck And Co., Inc. Thrombin inhibitors
JP2002284779A (ja) 2001-01-18 2002-10-03 Sankyo Co Ltd ヘテロアリール置換ピロール誘導体を含有する医薬
DE10108480A1 (de) 2001-02-22 2002-09-05 Bayer Ag Pyrazolylpyrimidine
US6958340B2 (en) 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors
US20030191121A1 (en) 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
GB0127929D0 (en) 2001-11-21 2002-01-16 Celltech R&D Ltd Chemical compounds
PL372390A1 (en) 2002-02-05 2005-07-25 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
WO2003075828A2 (en) 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
JP2005534632A (ja) 2002-05-10 2005-11-17 ニューロクライン バイオサイエンセズ， インコーポレイテッド メラノコルチンレセプターリガンドとしての置換ピペラジン
GB0212785D0 (en) 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
WO2004014384A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
EP1556360B1 (en) 2002-10-30 2008-01-23 Ciba SC Holding AG Electroluminescent device
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
WO2004039785A1 (en) 2002-11-01 2004-05-13 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
US20040097492A1 (en) 2002-11-01 2004-05-20 Pratt John K Anti-infective agents
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7569591B2 (en) 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
GB0306329D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Compounds
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
WO2005033072A2 (en) 2003-09-30 2005-04-14 Scios Inc. Heterocyclic amides and sulfonamides
JP4833069B2 (ja) 2003-10-01 2011-12-07 ゼンション・リミテッド テトラヒドロ−ナフタレンおよび尿素誘導体
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
US20050261497A1 (en) 2004-01-02 2005-11-24 Yuhei Yamamoto Catalytic asymmetric hetero diels-alder reaction of a heteroaromatic C-nitroso dienophile: a novel method for synthesis of chiral non-racemic amino alcohols
US20050153989A1 (en) 2004-01-13 2005-07-14 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
BRPI0507629A (pt) 2004-02-13 2007-07-03 Banyu Pharma Co Ltd composto, antagonista do receptor e agonista inverso do receptor da histamina h3, agente profilático ou terapêutico para uma doença metabólica, uma doença circulatória ou uma doença do sistema nervoso, ou um seu sal farmaceuticamente aceitável
AU2005219438B2 (en) 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
WO2005111003A1 (en) 2004-04-29 2005-11-24 Abbott Laboratories Amino-tetrazoles analogues and methods of use
US7285545B2 (en) 2004-05-03 2007-10-23 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
SE0401342D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
EA011671B1 (ru) 2004-06-04 2009-04-28 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
AU2005259983B2 (en) 2004-06-28 2011-07-28 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
AP2006003849A0 (en) 2004-06-28 2006-12-31 Incyte Corp 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2006039212A2 (en) 2004-09-29 2006-04-13 Portola Pharmaceuticals, Inc. Substituted 2h-1,3-benzoxazin-4(3h)-ones
BRPI0517272A (pt) 2004-10-29 2008-10-07 Tibotec Pharm Ltd derivados de pirimidina bicìclicos de inibição de hiv
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
JP4377942B2 (ja) 2005-02-25 2009-12-02 セレネックス， インコーポレイテッド テトラヒドロインドロン及びテトラヒドロインダゾロン誘導体
US7470693B2 (en) 2005-04-21 2008-12-30 Bristol-Myers Squibb Company Oxalamide derivatives as kinase inhibitors
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
DE102005023943A1 (de) 2005-05-20 2006-11-23 Grünenthal GmbH Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
EA015890B1 (ru) 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Производные пиримидина
FR2889189A1 (fr) 2005-07-28 2007-02-02 Cerep Sa Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1
WO2007021941A2 (en) 2005-08-16 2007-02-22 Icagen, Inc. Inhibitors of voltage-gated sodium channels
CA2621275A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
JP4531027B2 (ja) 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
JP2007126551A (ja) 2005-11-02 2007-05-24 Fujifilm Corp 蛍光性重合体微粒子、蛍光検出キット及び蛍光検出方法
GB0525337D0 (en) 2005-12-13 2006-01-18 Novartis Ag Organic compounds
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US7465795B2 (en) 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
KR20080083188A (ko) 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
JP2007186580A (ja) 2006-01-12 2007-07-26 Fujifilm Corp 重合体粒子、蛍光性重合体微粒子、重合体微粒子の製造方法、蛍光性重合体微粒子の製造方法、蛍光検出キット及び蛍光検出方法
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
FR2897061B1 (fr) 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
AU2007228784B2 (en) 2006-03-22 2012-03-08 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between MDM2 and p53
DOP2007000068A (es) 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
US20080076924A1 (en) 2006-06-30 2008-03-27 Patrick Betschmann Piperazines as P2X7 antagonists
AU2007269540B2 (en) 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
US20080021063A1 (en) 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
WO2008023159A1 (en) 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US20090325957A1 (en) 2006-08-24 2009-12-31 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
JP4776473B2 (ja) 2006-08-25 2011-09-21 株式会社ミツトヨ 光軸偏向型レーザ干渉計、その校正方法、補正方法、及び、測定方法
JP2008074892A (ja) 2006-09-19 2008-04-03 Fujifilm Corp 蛍光性重合体微粒子セット、蛍光検出用複合体セット、蛍光性重合体微粒子組成物及び蛍光検出方法
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
MX2009010037A (es) 2007-03-20 2009-11-05 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasas.
EP2014657A1 (de) 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
JP2010533158A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物類−９４５
JP2010533161A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物−９４６
JP2010533159A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物９４７
WO2009007750A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
US20090018166A1 (en) 2007-07-13 2009-01-15 Astrazeneca Ab New Pyridine Analogues X 161
JP5451611B2 (ja) 2007-07-26 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
CA2710016A1 (en) 2007-12-21 2009-07-02 The University Of Sydney Translocator protein ligands
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
EP2250999B1 (en) 2008-02-08 2016-04-13 Shiseido Company, Ltd. Skin whitening agent and external preparation for the skin
CN101998963B (zh) 2008-02-12 2014-09-24 陶氏益农公司 杀虫组合物
EP2262783A2 (en) 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
CA2720049A1 (en) 2008-03-31 2009-10-08 Zenyaku Kogyo Kabushikikaisha Pyrimidine derivative having cell protecting effect and uses thereof
CN101983197B (zh) 2008-04-18 2015-04-22 大熊制药株式会社 新型苯并噁嗪苯并咪唑衍生物、含有该衍生物的药物组合物及其用途
CA2723032A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
WO2009156484A2 (en) 2008-06-27 2009-12-30 Novartis Ag Organic compounds
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP2010030970A (ja) 2008-07-31 2010-02-12 Bayer Cropscience Ag 殺虫性ベンゼンジカルボキサミド誘導体
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022128A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022121A1 (en) 2008-08-20 2010-02-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
EA022417B1 (ru) 2008-10-21 2015-12-30 Саймабэй Терапевтикс, Инк. Арильные агонисты рецептора gpr120 и их применение
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
JP2012512252A (ja) 2008-12-17 2012-05-31 ブイアイエイ・ファーマシューティカルズ・インコーポレーテッド ジアシルグリセロールアシルトランスフェラーゼの阻害剤
PT2385832E (pt) 2009-01-08 2015-11-02 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
CA2753679C (en) 2009-02-27 2021-03-02 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TW201100428A (en) 2009-03-31 2011-01-01 Arqule Inc Substituted indolo-piperidine compounds
EP2414348B1 (en) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
WO2010135470A1 (en) 2009-05-19 2010-11-25 Intermune, Inc. Pifenidone derivatives for treating bronchial asthma
US8674109B2 (en) 2009-08-07 2014-03-18 Dow Agrosciences, Llc. Pesticidal compositions
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
TWI557127B (zh) 2009-09-04 2016-11-11 百健Ｍａ公司 布魯頓氏酪胺酸激酶抑制劑
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
RS53716B1 (sr) 2009-10-19 2015-04-30 Synta Pharmaceuticals Corp. Kombinovana terapija kancera sa hsp90 inhibitornim jedinjenjima
KR20110049217A (ko) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8609866B2 (en) 2009-12-18 2013-12-17 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2011094572A2 (en) 2010-01-28 2011-08-04 Shuichi Takayama Hanging drop devices, systems and/or methods
WO2011105572A1 (ja) 2010-02-26 2011-09-01 持田製薬株式会社 新規ヘテロアリール誘導体
CA2793223A1 (en) 2010-03-16 2011-09-22 Aventis Pharmaceuticals Inc. Substituted pyrimidines as prostaglandin d2 receptor antagonists
US8691810B2 (en) 2010-05-12 2014-04-08 Abbvie Inc. Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases
CA2800578A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen-heterocyclic compounds as phosphodiesterase 10 inhibitors
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2616469B1 (en) 2010-09-14 2016-10-26 Exelixis, Inc. 9h-purine compounds as pi3k-delta inhibitors and methods for their manufacture
RU2596185C2 (ru) 2010-09-29 2016-08-27 Интервет Интернэшнл Б.В. N-гетероарильные соединения
ES2624845T3 (es) 2010-09-29 2017-07-17 Intervet International B.V. Compuestos de N-heteroarilo con unidad de puente cíclico para el tratamiento de enfermedades parasitarias
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
DE102010050558A1 (de) 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-Pyrrolo[2,3-b]pyridinderivate
US8729102B2 (en) 2010-11-30 2014-05-20 Takeda Pharmaceutical Company Limited Bicyclic compound
WO2012074022A1 (ja) 2010-12-01 2012-06-07 旭硝子株式会社 イリジウムカチオン錯体および発光組成物
WO2012103336A1 (en) 2011-01-26 2012-08-02 University Of Rochester Small molecule rnase inhibitors and methods of use
AR085908A1 (es) 2011-03-16 2013-11-06 Hoffmann La Roche DERIVADOS DE 3-BUTIN-2-OL Y DE CARBONITRILO CON ACTIVIDAD INHIBIDORA DE LA QUINASA INDUCTORA DE NF-kB (NIK)
EP2697196A1 (en) 2011-04-13 2014-02-19 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
RS55123B1 (sr) 2011-05-27 2016-12-30 Achillion Pharmaceuticals Inc Supstituisani alifani, ciklofani, heterafani, heterofani, hetero-heterafani i metaloceni korisni za lečenje infekcija hepatitis c virusa
SG194770A1 (en) 2011-05-27 2013-12-30 Probiodrug Ag Radiolabelled glutaminyl cyclase inhibitors
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013019824A2 (en) 2011-08-02 2013-02-07 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
EP2739143B1 (en) 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
SG11201400456RA (en) 2011-09-09 2014-04-28 Univ New York Amido compounds as ror?tmodulators and uses thereof
WO2013052526A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. Triazolyl pde10 inhibitors
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
US9663521B2 (en) 2011-12-16 2017-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis
CN103159738B (zh) 2011-12-19 2016-09-07 上海泓博智源医药股份有限公司 炔基桥连的杂芳香化合物及其应用
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2013117649A1 (en) 2012-02-10 2013-08-15 Galapagos Nv Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases
EP2822926A4 (en) 2012-03-07 2015-11-04 H Lee Moffitt Cancer Ct & Res SELECTIVE HISTON DEACTY LASE-6 HEMMER
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
CN102786512A (zh) 2012-05-31 2012-11-21 中国人民解放军军事医学科学院毒物药物研究所 N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用
JP2014078482A (ja) 2012-06-08 2014-05-01 Fujifilm Corp 非水電解液二次電池および非水電解液
RU2015102537A (ru) 2012-06-28 2016-08-20 Эббви Инк. Цианогуанидины и их применение в качестве противовирусных средств
WO2014011911A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP2015525775A (ja) 2012-07-23 2015-09-07 メルク パテント ゲーエムベーハー リガンドおよびその製造方法
TWI719468B (zh) 2012-07-24 2021-02-21 日商日產化學股份有限公司 培養基組成物、其用途、細胞或組織之培養方法及細胞或組織培養物
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
CN104507923B (zh) 2012-08-02 2018-02-09 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代的吡咯类活性剂
WO2014185358A1 (ja) 2013-05-14 2014-11-20 国立大学法人京都大学 効率的な心筋細胞の誘導方法
EP3048169B1 (en) 2013-09-04 2019-07-10 Otsuka Pharmaceutical Factory, Inc. Method for preparing pluripotent stem cells
CN103588795A (zh) 2013-11-27 2014-02-19 中国科学院福建物质结构研究所 一类离子型一价铜发光配合物及其应用
CN113046237A (zh) 2014-02-25 2021-06-29 康宁股份有限公司 球状体制造装置、球状体的回收方法及制造方法
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
AU2015349890B2 (en) 2014-11-21 2018-08-30 Merck Sharp & Dohme Llc Insulin receptor partial agonists
CA2968434A1 (en) 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
US9695280B2 (en) 2015-03-03 2017-07-04 Ricoh Co., Ltd. Methods for solid freeform fabrication

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514676A (ja) 2006-12-21 2010-05-06 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
WO2012020762A1 (ja) 2010-08-10 2012-02-16 アステラス製薬株式会社 へテロ環化合物
JP2017523193A (ja) 2014-08-04 2017-08-17 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ 核内受容体に対して活性な化合物
JP2017523192A (ja) 2014-08-04 2017-08-17 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ 炎症性、代謝性、腫瘍性および自己免疫疾患の処置に有用なピリミジンの任意選択により縮合されているヘテロシクリル置換誘導体

Also Published As

Publication number Publication date
US20210188828A1 (en) 2021-06-24
CA3160522A1 (en) 2021-06-24
EP4076657A1 (en) 2022-10-26
WO2021124277A1 (en) 2021-06-24
MX2022007265A (es) 2022-09-09
JP2021098692A (ja) 2021-07-01
US11447479B2 (en) 2022-09-20
AU2020405446A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
JP7746259B2 (ja) 核内受容体に対して活性の化合物
US11447479B2 (en) Compounds active towards nuclear receptors
CA2957046C (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
JP2023524439A (ja) Ｂｃｌ－２タンパク質阻害剤
WO2011146300A1 (en) Novel prolylcarboxypeptidase inhibitors
CA3160522C (en) Compounds active towards nuclear receptors
JP7713954B2 (ja) 核内受容体に対して活性な化合物
JP7713953B2 (ja) 核内受容体に対して活性な化合物
CA3160508C (en) Substituted ((((6-benzylamino-5-fluoropyrimidin-4-yl)amino)methyl)-piperidin-1-yl)acetamide compounds active towards nuclear receptors
HK40077526B (en) Compounds active towards nuclear receptors
EA047629B1 (ru) Соединения, активные в отношении ядерных рецепторов
TW202014191A (zh) 具有選擇性ｂａｃｅ１抑制活性的四氫哌喃并衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250812

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260403

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260421

R150 Certificate of patent or registration of utility model

Ref document number: 7854780

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150